Title:Tuberculosis Treated by Multiple Drugs: An Overview
Volume: 15
Issue: 3
Author(s): Gyanendra Singh, Prashant Kesharwani*Anand Kumar Srivastava*
Affiliation:
- The International Medical University, School of Pharmacy, Department of Pharmaceutical Technology, Jalan Jalil Perkasa 19, 57000 Kuala Lumpur,Malaysia
- Department of Pharmaceutics, Indian Institute of Technology, Banaras Hindu University, (IIT-BHU), UP-221005, Varanasi,India
Keywords:
Tuberculosis, co-infection, tuberculosis regimen, Mycobacterium tuberculosis, Purified Protein Derivative (PPD).
Abstract: Background: Tuberculosis is an infection and caused by gentle growing bacteria. The Internet
provides opportunities for people with tuberculosis (TB) to connect with one another to address
these challenges.
Objective: The aim of this paper is to introduce readers to the platforms on which Tuberculosis participants
interact, to discuss reasons for and risks associated with TB-related activity, and to review research
related to the potential impact of individual participation on TB outcomes.
Methods: Research and online content related to Tuberculosis online activity is reviewed, however, the
difficulty in accurate prescribing and adhering to these protocols and the emergence of M. tuberculosis
strains resistant to multiple drugs and drug-drug interactions that interfere with optimal treatment of
Tuberculosis and co-infected patients with the different disease has generated a pressing need for improved
Tuberculosis therapies.
Results: Together with the ominous global burden of Tuberculosis, those shortcomings of current medication
have contributed to a renewed interest in the development of improved drugs and protocols for
the medication of Tuberculosis. This article features obstacles related with the enhanced utilization of
existing drugs and difficulties related with the advancement of enhanced products, concentrating on
perspectives characteristic in Tuberculosis drug clinical improvement. The participation includes peer
support, advocacy, self-expression, seeking and sharing TB information, improving approaches to Tuberculosis
data management, and humour.
Conclusion: This article highlights hurdles related to the optimised use of existing drugs and challenges
related to the development of improved products, focusing on aspects inherent in Tuberculosis drug
clinical development. Concluding comments offer processes for more efficient development of Tuberculosis
therapies and increase the quality of life.
